Accelerating Medicines Partnership – Alzheimer’s disease

On February 4, 2014 the National Institutes of Health (NIH) announced the formation of the new Accelerating Medicines Partnership (AMP) to focus on three areas of research, including Alzheimer’s disease. This partnership, which brings together high level government entities, 10 biopharmaceutical companies and several non-profit organizations, is intended to identify and validate biomarkers of disease and targets drug development. Data generated from these studies will be made publicly available, an unprecedented approach that will be a positive step for researchers and ultimately patients.

The press announcement from the NIH on the AMP Alzheimer’s initiative validates GliaCure’s approach as it highlights the roles of inflammation and amyloid beta in the disease, both of which GliaCure’s program addresses. The announcement also highlights the current absence of validated biomarkers for the disease, a factor that has limited the ability of drug development groups to perform effective clinical trials.